Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
Cantor Fitzgerald
UBS
Chinese Patent Office
Federal Trade Commission
Julphar
Merck
Medtronic
Fish and Richardson

Generated: May 24, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,067,451

« Back to Dashboard

Which drugs does patent 8,067,451 protect, and when does it expire?

Patent 8,067,451 protects DUEXIS and is included in one NDA.

This patent has twenty-two patent family members in fourteen countries.
Summary for Patent: 8,067,451
Title:Methods and medicaments for administration of ibuprofen
Abstract: A method for administration of ibuprofen to a subject in need of ibuprofen treatment is provided, in which an oral dosage form comprising a therapeutically effective amount of ibuprofen and a therapeutically effective amount of famotidine is administered three times per day.
Inventor(s): Tidmarsh; George (Portola Valley, CA), Golombik; Barry L. (Incline Village, NV), Sharma; Puneet (Gaithersburg, MD)
Assignee: Horizon Pharma USA, Inc. (Northbrook, IL)
Application Number:11/779,204
Patent Claim Types:
see list of patent claims
Compound; Dosage form; Composition; Process; Use;

Drugs Protected by US Patent 8,067,451

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Horizon Pharma DUEXIS famotidine; ibuprofen TABLET;ORAL 022519-001 Apr 23, 2011 RX Yes Yes ➤ Sign Up ➤ Sign Up Y RELIEF OF SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS AND TO DECREASE RISK OF DEVELOPING UPPER GASTROINTESTINAL ULCERS IN PATIENTS WHO ARE TAKING IBUPROFEN FOR THOSE INDICATIONS ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,067,451

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,318,202 Stable compositions of famotidine and ibuprofen ➤ Sign Up
8,067,033 Stable compositions of famotidine and ibuprofen ➤ Sign Up
8,501,228 Stable compositions of famotidine and ibuprofen ➤ Sign Up
8,449,910 Stable compositions of famotidine and ibuprofen ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Cipla
Fish and Richardson
Johnson and Johnson
McKesson
Dow
Harvard Business School
Colorcon
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.